33rd International Vicenza Course on Critical Care Nephrology: Presentation Collection

Opening Ceremony

• Opening Remarks – C. Ronco
• Welcome from Italian Society of Nephrology – R. Coppo
• International Society for Hemodialysis award for best abstracts –M. Misra
• Invited Opening Lecture: The future of health care reform – A.Milburn

Session 1: Epidemiology of AKI 

• The Search for a Standard of Care – J.Hegbrant
• Risk Management: working for safety – J.Bosch
• The Medical Director: working efficacy – A. Nissenson
• Delivering optimal quality of care managing all stakeholders’ interests – A.Stopper

Session 2: AKI – ICT and Economics, Debate on Renal Angina

• Electronic Records & Sniffers – K. Kashani
• The Health Economics of AKI – A. Lewington
• Renal Angina: New Concept, Perfect Term – L.S. Chawla
• Renal Angina: Right Concept, Wrong Name  – P. Palevsky

Session 3: RRT in AKI and Critical Illness

• Uric acid: metabolic and cardiovascular risk – A. Covic
• Micro inflammation and endothelial damage in CKD and hemodialysis – P. Aljama
• Biomarkers of chronic inflammatory state in uremia and CVD – V. Panichi
• The burdne of cardiovascular risk in CKD and dialysis patients (CRS Type 4) – A.House
• Disparities of treatment for ACS and Heart Failure in CKD patients – P. Mc Cullough

Session 4: Multiple Organ Support Therapies

• Is Dialysis Catheter harming the patient? – M. Kuhlmann
• The evils of intradialytic sodium loading – P. Kotanko
• Is AV fistula harming the patient? – R. Amerling
• The concept of wet and dry BNP – A. Maisel
• The wonders of ultrasonography – M. Pittiruti

Session 5: Biomarkers of AKI

• Recent trials on Hemodiafiltration – F.Locatelli
• The treatment of HCV with Affinity Plasmapheresis on Dialysis Machines – R. Kenley
• From High flux to super high flux – M. Kuhlmann
• Antioxidant dialytic approach with vitamin E coated membranes – F. Nalesso
• Light chain removal: HCO membranes – A. Santoro

Session 6: AKI – Pathophysiology, Prevention, Recovery, Progression

• Statins and lipid lowering strategies in cardio-renal patients – S.Bianchi
• Results from recent trials – D. de Zeeuw
• Factors determining insulin resistance in hemodialysis patients – A. Ikizler
• The spectrum of metabolic alterations in dialysis – M. Misra
• Lipid disorders in uremia and dialysis – W.Keane
• New insights on inflammation and protein energy wasting in CKD – P.Stenvinkel

Session 7: CardioRenal Crosstalk 

• VDR Activators: clinical outcomes – A. Covic
• Restoring the physiology of VDR activation and the concept of selectivity – M. Cozzolino
• The impact of paricalcitol on CKD progression measured by albuminuria (The VITAL study) – D. de Zeeuw
• The impact of paricalcitol on LVH (The PRIMO study) – M. Cozzolino
• VDRA: Implications to daily practice – D. Warnock

Session 8: Fluid management

• Blood Volume & Biofeedback – A.Santoro
• Body composition and Heart rate variability to achieve dry weight and tolerance – F. Nalesso
• Extracorporeal Ultrafiltration for congestive heart failure patients – M.R. Costanzo
• BIVA + BNP in the emergency room – S. Di Somma

Session 9: Critical Care Nephrology Issues

• AKI Biomarkers and endpoints for Clinical Trials – P. Murray
• AKI: can we prevent it? – P. Mc Cullough
• Impact of AKI on CKD and its progression – M.Okusa
• Special Lecture: Acute Kidney Injury and its management – J. Kellum

Session 10: New Horizons in AKI and CRRT

• Financial implications from application of wearable technology – R. Greenwood
• Clinical benefits of a wearable approach – A. Davenport
• The WAK project: where are we? – V. Gura
• Wearable dialysis: what is missing – H.D. Polaschegg
• Wearable ultrafiltration for heart failure – C. Ronco

Session 11: Anemia and its management

• New ESAs and new Iron formulations – F. Locatelli
• Impact of dialytic technique on anemia – V. Panichi
• Anemia Trials in CKD and Clinical practice: Refining the approach to ESA’s use – A. De Francisco
• Anemia and Hypoalbuminemia as Prognostic Indicators in HD: Fact or Artefact? – R. Amerling
• Anemia in HD and PD: similar treatments? – J. Burkart
• The Cardio Renal Anemia syndrome – S. von Heahling